

Press release from Emotra AB (publ)
Göteborg, September 1, 2015

Communiqué from extraordinary general meeting of shareholders in Emotra AB (publ)

Today, on September 1, 2015, Emotra AB (publ) held an extraordinary general meeting of shareholders. The resolutions, summarised below, were adopted with the necessary majority.

Resolution on amendment of the Articles of Association

The Meeting resolved to amend firstly § 4 of the Articles of Association, whereby the limits for the share capital shall be not less than 960,438.6 SEK and a maximum of 3,841,754.4 SEK, secondly § 5 whereby the number of shares shall be not less than 5,191,560 and not more than 20,766,240, thirdly § 6, whereby the Board of Directors shall comprise a minimum of three and a maximum of six members, with a minimum of zero and a maximum of two deputies, fourthly § 7 whereby the company shall have one or two auditors with a minimum of zero and a maximum of two deputy auditors, and fifthly § 12 concerning participation in the General Meeting to the following: the shareholders who are entitled to attend the meeting are those who have been entered in the share register as prescribed in Chapter 7, § 28, subparagraph 3 of the Companies Act and who have acknowledged participation no later than the date specified in the notice to the meeting. This day must not be a Sunday, other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year's Eve, nor a date more than five weekdays before the meeting. If the shareholder intends to involve proxies, then the number of proxies must be given in the acknowledgement.

Furthermore, the Extraordinary General Meeting resolved that the existing § 10 of the Articles of Association regulating voting should be deleted.

Resolution authorising the Board to issue new shares

The EGM resolved to authorise the Board to issue new shares, on one or more occasions up until the next AGM, with or without deviation from the shareholders' preferential rights.

The number of shares issued under the authorisation shall correspond to a maximum amount of 15 MSEK in total issue proceeds.

The issues will be made at the market subscription price, subject to customary issue discount, where applicable, and payment must be in cash.

If the board decides on a new issue deviating from the shareholders' preferential rights, the reason should be diversification of ownership.

For further information, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*